Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement-Reference-Cited by-同舟云学术

Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement

Published:2024-05-01 Issue:5 Volume:181 Page:457-459
ISSN:0002-953X
Container-title:American Journal of Psychiatry
language:en
Short-container-title:AJP

Author:

Williams Arthur Robin¹,Mauro Christine M.¹,Huber Ben¹,Chiodo Lisa¹,Crystal Stephen¹,Samples Hillary¹,Olfson Mark¹

Affiliation:

1. Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for...

Publisher

American Psychiatric Association Publishing

Reference14 articles.

1. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size

2. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”

3. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US

4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Substance Use Disorders: Confronting Addiction From Prevention to Recovery;American Journal of Psychiatry;2024-05-01